Abstract 2888: Targeting the fatal pediatric brain tumors AT/RT and DIPG with the DNA binding agent quinacrineHarpreet Kaur, Eric H. Raabe, Charles G. Eberhart et al.|Cancer Research|2019Cited by 0
Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic targetRachael Maynard, Sariah J. Allen, Eric H. Raabe et al.|UNC Libraries|2020Cited by 0
The Chromatin-Modifying Protein HMGA2 Promotes Atypical Teratoid/Rhabdoid Cell TumorigenicityBernard E. Weissman, Eric H. Raabe, Charles G. Eberhart et al.|UNC Libraries|2020Cited by 0
Figure S5 from Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-NorleucineSabrina Wang, Jeffrey Rubens, Brad Poore et al.|Unknown|2023Cited by 0
Figure S6 from Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-NorleucineSabrina Wang, Jeffrey Rubens, Brad Poore et al.|Unknown|2023Cited by 0